Johnson & Johnson Talc Settlement Amounts Settlement

Johnson & Johnson has disclosed two different present-value figures for resolving ovarian cancer talc claims. On May 1, 2024, its subsidiary LLT Management LLC proposed a plan with a present value of approximately $6.475 billion over 25 years. On September 20, 2024, its subsidiary Red River Talc LLC increased that commitment to approximately $8 billion present value, or approximately $10 billion nominal, over 25 years.

At a glance

• The May 1, 2024 LLT plan committed a present value of approximately $6.475 billion, paid over 25 years, according to Johnson & Johnson’s SEC-filed announcement.
• The September 20, 2024 Red River plan increased the commitment by $1.75 billion, to approximately $8 billion present value and approximately $10 billion nominal.
• Johnson & Johnson recorded an incremental charge of approximately $2.7 billion in the first quarter of 2024, for a total reserve of approximately $11.0 billion, or $13.7 billion nominal payable over 25 years.
• The $8 billion figure splits into an additional $1.1 billion committed to the bankruptcy trust and $650 million the Company agreed to contribute toward plaintiffs’ counsel legal fees and expenses.
• Red River filed its prepackaged Chapter 11 case in the U.S. Bankruptcy Court for the Southern District of Texas on September 20, 2024, with approximately 83% of current claimants supporting the plan.

What is established vs. what is alleged

The dollar figures above are company disclosures, not court awards. Each comes from a document Johnson & Johnson filed with the U.S. Securities and Exchange Commission (SEC) or a periodic report it filed there. The May 1, 2024 press release is Exhibit 99.2 to a Johnson & Johnson SEC filing. The September 20, 2024 press release is Exhibit 99.1 to a later filing.

Those documents describe the money as a proposed settlement commitment under a prepackaged Chapter 11 plan. “Present value” means the amount after discounting future payments to today’s dollars; the same documents give the nominal total that will actually be paid over 25 years. The press releases also carry forward-looking statement cautions stating that the Company cannot predict the timing, ultimate outcome or financial impact of the matter.

Johnson & Johnson’s position on the underlying claims is stated plainly in the same releases. The Company “reiterates that none of the talc-related claims against it have merit” and says the claims rest on allegations that independent experts and governmental and regulatory bodies have rejected for decades. That is the Company’s characterization, not a court finding recited in these documents.

The releases also make litigation-outcome assertions that are company statements. They state that the Company has prevailed in approximately 95% of ovarian cases tried to date, including every ovarian case tried over the last six years, and that most ovarian claimants have not recovered and will not recover anything at trial. None of the supplied documents include the underlying verdict records or docket entries behind those percentages.

How the settlement figures changed between May and September 2024

The May 2024 announcement came from LLT Management LLC, a Johnson & Johnson subsidiary, and described a proposed Plan of Reorganization for ovarian cancer claims arising from cosmetic talc. The release said the ovarian claims covered by that plan constituted 99.75% of the pending talc lawsuits against the Company and its affiliates in the United States. It said the plan would resolve those claims through a consensual prepackaged Chapter 11 after a three-month solicitation period, with a 75% claimant vote threshold.

The September 2024 announcement came from a different subsidiary, Red River Talc LLC. It said Red River filed a voluntary prepackaged Chapter 11 case in the U.S. Bankruptcy Court for the Southern District of Texas on September 20, 2024. The release said approximately 83% of current claimants supported the plan, above the 75% approval threshold the release attributes to the U.S. Bankruptcy Code, and that the Future Claims Representative also supported it.

The increase was itemized in that release. Red River agreed to commit an additional $1.1 billion to the bankruptcy trust for distribution to claimants. The Company backed Red River’s commitments and agreed to contribute an additional $650 million to resolve claims for legal fees and expenses sought by plaintiffs’ counsel for leadership roles in the multi-district litigation. Added to the earlier commitment, the release describes an aggregate present value of approximately $8 billion, totaling approximately $10 billion nominal over 25 years.

Two limits on scope appear in both releases. The remaining pending personal injury lawsuits, which relate to mesothelioma, are being addressed outside the plan, and the Company said it had already resolved 95% of mesothelioma lawsuits filed to date. State consumer protection claims are also addressed outside the plan, and the Company said it had agreements in principle to resolve talc-related claims in the bankruptcy cases of its talc suppliers, Imerys Talc America, Inc. and Cyprus Mines Corporation.

Where the claims stand procedurally

The settlement figures sit inside a bankruptcy proceeding, not a single consolidated trial. The Chapter 11 case was filed by Red River Talc LLC in the U.S. Bankruptcy Court for the Southern District of Texas on September 20, 2024, according to the Company’s release. The release describes the plan as subject to confirmation by that court and states that the Company expected it to be expeditiously confirmed. The supplied documents do not include a confirmation order.

Most ovarian claims are not in the bankruptcy case but in a multi-district litigation (MDL), a federal procedure that consolidates pretrial proceedings for many similar cases before one judge. The May 2024 release states that 93% of the ovarian claims are filed in that MDL and that on March 27, 2024, the presiding judge agreed to reconsider the scientific validity of plaintiffs’ expert opinions at a Daubert hearing, a proceeding on whether expert testimony is admissible under Federal Rule of Evidence 702.

The releases also describe a parallel track. While plan solicitation was pending, the Company said it remained committed to appealing the dismissal of LLT’s prior bankruptcy case, litigating against claimants who elect not to settle, and pursuing affirmative claims against experts and plaintiff law firms. The supplied documents do not identify the appellate court, a docket number for the appeal, or any ruling on it.

The MDL itself is not named in these documents. The supplied sources do not give the MDL number, the name of the transferee court, or the Judicial Panel on Multidistrict Litigation (JPML) transfer order, so this article does not state one. For background on the broader case history, see the Johnson & Johnson talc litigation overview and the Johnson & Johnson talc litigation case study.

The reserve figure and what it covers

The reserve and the settlement commitment are different numbers and should not be read as the same thing. The May 2024 release states that the Company recorded an incremental charge of approximately $2.7 billion in the first quarter of 2024, for a total reserve of approximately $11.0 billion, or $13.7 billion nominal payable over 25 years. The release says the reserve was set “to account for these settlements and the comprehensive resolution of the ovarian claims through the Plan,” which means it spans more than the ovarian commitment alone.

The $6.475 billion present-value commitment and the later approximately $8 billion present-value commitment are the ovarian settlement amounts described in the releases. The reserve is an accounting entry covering the settlements described in the release as a group. A reader comparing the figures should keep the two categories separate; the supplied documents do not break the reserve down line by line.

Key dates

• March 27, 2024: the MDL judge agreed to reconsider the scientific validity of plaintiffs’ expert opinions at a Daubert hearing, per the May 1, 2024 release.
• First quarter of 2024: Johnson & Johnson recorded an incremental charge of approximately $2.7 billion, for a total reserve of approximately $11.0 billion.
• May 1, 2024: LLT Management LLC announced a proposed prepackaged reorganization with a present value of approximately $6.475 billion over 25 years.
• July 2023: the New Jersey Bankruptcy Court dismissed LLT’s prior bankruptcy case, a decision the May 2024 release quotes as encouraging a comprehensive resolution through another bankruptcy.
• September 20, 2024: Red River Talc LLC filed a voluntary prepackaged Chapter 11 case in the U.S. Bankruptcy Court for the Southern District of Texas, with approximately 83% claimant support and a commitment increased by $1.75 billion to approximately $8 billion present value.
• July 2023 onward: the Company said it would appeal the dismissal of LLT’s prior bankruptcy case; the supplied documents give no appellate ruling.

What this does not establish

The record supplied here does not establish that any claimant has been paid. It does not include a bankruptcy court confirmation order for the Red River plan, a distribution schedule, or a per-claimant payment amount. Nothing in the documents states how the approximately $8 billion would be divided among claimants, and no per-person figure should be inferred from it.

The record also does not establish liability. The releases state the Company’s position that the claims lack merit; they do not contain a court finding on the safety of talc products or on causation for any individual claimant. The trial-win percentages and the statement that most claimants will recover nothing at trial are the Company’s own characterizations.

Finally, the documents do not identify the MDL number or transfer order, do not provide JPML docket counts, and do not state the outcome of any appeal of the prior bankruptcy dismissal. The furnished SEC filings are financial reports and press exhibits; their exhibits in these excerpts do not include the narrative talc discussion or the case counts that a full 10-Q or 10-K would carry.

Frequently asked questions

How much has Johnson & Johnson committed to talc settlements?

Johnson & Johnson’s subsidiary Red River Talc LLC committed approximately $8 billion in present value, or approximately $10 billion nominal paid over 25 years, according to a Johnson & Johnson press release filed with the SEC on September 20, 2024. That figure followed an earlier May 1, 2024 commitment by its subsidiary LLT Management LLC of approximately $6.475 billion present value. Both figures are proposed settlement commitments under a prepackaged Chapter 11 plan, not amounts paid to date.

What is the difference between present value and nominal value in the Johnson & Johnson talc settlement?

Present value discounts future payments to today’s dollars, while nominal value is the total of the payments as they will actually be made. The September 20, 2024 Johnson & Johnson release describes the Red River commitment as approximately $8 billion present value and approximately $10 billion nominal, paid over 25 years. The earlier May 1, 2024 release gave only a present-value figure of approximately $6.475 billion over the same 25-year period.

Is the Johnson & Johnson talc settlement final?

The supplied documents do not show that the Red River Talc LLC plan has been confirmed. Red River filed the prepackaged Chapter 11 case in the U.S. Bankruptcy Court for the Southern District of Texas on September 20, 2024, and Johnson & Johnson stated it expected the court to confirm the plan. The releases caution that the Company cannot predict the timing, ultimate outcome or financial impact of the matter.

How many talc lawsuits does the Johnson & Johnson plan cover?

The May 1, 2024 Johnson & Johnson release states that the ovarian claims to be resolved by the plan constitute 99.75% of the pending talc lawsuits against the Company and its affiliates in the United States. The remaining pending personal injury lawsuits relate to mesothelioma and are addressed outside the plan. The same release states that 93% of the ovarian claims are filed in the multi-district litigation.

Did a court approve the settlement amounts?

The supplied documents do not include a court order approving the amounts. The dollar figures come from Johnson & Johnson press releases filed as exhibits with the SEC and describe what the Company and its subsidiary committed under a proposed plan. Whether a bankruptcy court confirms the plan is a separate step that the furnished documents leave unresolved. Readers can see how comparable mass tort matters have moved through consolidation in the 3M Combat Arms earplug settlement amounts analysis.

Sources

1. U.S. Securities and Exchange Commission (Johnson & Johnson Exhibit 99.2): “Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims” (link, accessed 2026-05-26)
2. U.S. Securities and Exchange Commission (Johnson & Johnson Exhibit 99.1): “Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case” (link, accessed 2026-05-26)
3. U.S. Securities and Exchange Commission: “Johnson & Johnson Form 10-Q, quarter ended March 30, 2025” (link, accessed 2026-05-26)
4. U.S. Securities and Exchange Commission: “Johnson & Johnson Form 10-Q, quarter ended April 2, 2023” (link, accessed 2026-05-26)
5. U.S. Securities and Exchange Commission: “Johnson & Johnson Form 10-Q, quarter ended September 28, 2025” (link, accessed 2026-05-26)
6. U.S. Securities and Exchange Commission: “Johnson & Johnson Form 10-Q, quarter ended April 3, 2022” (link, accessed 2026-05-26)